51 research outputs found

    Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

    Get PDF
    The antiresorptive potency varies between different bisphosphonates. We investigated the effect of stopping oral bisphosphonate treatment for postmenopausal osteoporosis (ibandronate, alendronate, risedronate) on BTMs and BMD. After stopping treatment, all three groups showed an increase in BTMs and a decrease in hip BMD; however, none returned to pre-treatment baseline values. INTRODUCTION: Bisphosphonates (BPs) continue to suppress bone turnover markers (BTMs) after treatment has stopped, leading to the suggestion that a pause in treatment could be considered for low-risk patients. Indirect comparisons suggest that after cessation of treatment, the effects on bone may differ between drugs. We investigated the effects of stopping oral BP treatments for postmenopausal osteoporosis on BTMs and bone mineral density (BMD). METHODS: We studied postmenopausal osteoporotic women who had previously taken part in a 2-year randomised study of three oral BPs (ibandronate, alendronate, or risedronate). At the end of the study, women with hip BMD T-score > - 2.5 and considered clinically appropriate to discontinue treatment were invited to participate in a further 2-year observational study. Biochemical response was assessed using BTMs, and BMD was measured by dual-energy X-ray absorptiometry. RESULTS: All BTMs increased after treatment withdrawal but remained below the pre-treatment baseline with less suppression of BTMs for the risedronate group compared to alendronate and ibandronate up to 48 weeks. There was no difference between the BP groups 96 weeks after stopping treatment. The change in BMD during the 96 weeks after stopping treatment was - 1.6% (95% CI - 1.9 to - 1.2, P < 0.001) for the total hip and - 0.6% (95% CI - 1.1 to - 0.2, P = 0.17) at the lumbar spine with no difference between the three BP groups (P = 0.85 and P = 0.48, respectively). CONCLUSION: For all treatment groups, there was an increase in BTMs and a decrease in hip BMD after stopping BPs for 2 years; however, none returned to pre-treatment baseline values

    Powerful owls : possum assassins move into town

    No full text
    Once thought to live only in large forested areas, the powerful owl (Ninox strenua), Australia’s largest and most iconic of owls (figure 11.1), surprisingly is now turning up frequently in the cities of eastern Australia. Powerful owls require ample prey and large tree cavities for nest sites how this top-order predator is able to survive in human-dominated landscapes is an important question for conservation and the focus of ongoing research. The powerful owl is endemic to Australia, resident in the three eastern mainland states and the Australian Capital Territory, and classified nationally as “rare.”2,3 First described by Gould in 1838, powerful owls are an unusual raptor in that they do not exhibit reversed sexual size dimorphism, the prevalent trait among raptors in which females are larger than males. For reasons still not understood, male powerful owls grow to a height of 65 cm and weigh up to 1,700 g, compared to females, which grow to a height of 54 cm and weigh up to 1,308 g.
    • …
    corecore